European Patent Office Grants Palvella Patent for QTORIN Rapamycin
WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) said the European Patent Office has granted a patent covering its lead product candidate QTORIN 3.9% rapamycin gel, extending intellectual property protection …
European Patent Office Grants Palvella Patent for QTORIN Rapamycin Read More